Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T18:21:31.562Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacologic Treatment of Bipolar Disorder

Published online by Cambridge University Press:  07 November 2014

Claudia Baldassano
Get access Rights & Permissions [Opens in a new window]

Extract

Regarding the treatment of patients with bipolar disorder, positive findings have shown that patients engaged in treatment may live longer. Angst and Sellaro studied standardized mortality ratios for patients with bipolar disorder and found a significant reduction in mortality ratio in our bipolar patients who were actively in treatment (Slide 1). Data from the Collaborative Depression Study by Judd and colleagues showed that bipolar patients are quite symptomatic. Judd and colleagues followed bipolar patients over a 13-year period and found that these patients were symptomatic ~50% of the study period. What were these patients most likely to be symptomatic with: bipolar depression (Slide 2). Thus, it is important to focus on bipolar depression and examine placebo-controlled trials that were adequately powered in its treatment.

Over the last decade, there have been positive trials studying lamotrigine, quetiapine, olanzapine, and olanzapine-fluoxetine combination. Two of these medications are United States Food and Drug Administration—approved in bipolar disorder treatment: quetiapine and olanzapine-fluoxetine. There are a number of negative trials in bipolar depression, including a number of antidepressant monotherapy trials and antidepressants in combination with mood stabilizers (Slide 3). However, what is the most frequent pharmacotherapy treatment used for bipolar depression? It is the use of antidepressants alone; antidepressant monotherapy is twice as commonly prescribed as mood stabilizers (Slide 4). Thus, it is necessary for clinicians to possess knowledge of the evidence and results from both positive and negative antidepressant trials for bipolar disorder.

Type
Research Article
Information
CNS Spectrums , Volume 15 , supplement S3: Recognition and Treatment Strategies for Bipolar Disorder Across the Life Cycle , February 2010 , pp. 10 - 13
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Angst, J, Sellaro, R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry. 2000;48(6):445-457.CrossRefGoogle ScholarPubMed
2.Judd, LL, Schettler, PJ, Solomon, DA, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord. 2008:108(1-2):49-58.CrossRefGoogle ScholarPubMed
3.Calabrese, JR, Sowden, CL, Sachs, GS, Ascher, JA, Monaghan, E, Rudd, GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999:60(2):79-88.CrossRefGoogle ScholarPubMed
4.Tohen, M, Vieta, E, Calabrese, J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003:60(11):1079-1088.CrossRefGoogle ScholarPubMed
5.Calabrese, JR, Keck, PE Jr, Macfadden, W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005:162(7):1351-1360.CrossRefGoogle ScholarPubMed
6.Nemeroff, CB, Evans, DL, Gyulai, L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001:158(6):906-912.CrossRefGoogle ScholarPubMed
7.McElroy, S, et al. Presented at: 3rd Biennial Conference of the International Society for Bipolar Disorders: January 27-28, 2008: Delhi, India.Google Scholar
8.Sachs, GS, Nierenberg, AA, Calabrese, JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722.CrossRefGoogle ScholarPubMed
9.Peet, M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994:164(4):549-550.CrossRefGoogle ScholarPubMed
10.Leverich, GS, Altshuler, LL, Frye, MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006:163(2):232-239.CrossRefGoogle ScholarPubMed
11.Post, RM, Altshuler, LL, Leverich, GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006:189:124-131.CrossRefGoogle ScholarPubMed
12.Frye, MA, Calabrese, JR, Reed, ML, et al. Use of health care services among persons who screen positive for bipolar disorder. Psychiatr Serv. 2005:56(12):1529-1533.CrossRefGoogle ScholarPubMed
13.Baldessarini, RJ, Leahy, L, Arcona, S, Gause, D, Zhang, W, Hennen, J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007:58(1):85-91.CrossRefGoogle ScholarPubMed
14.Zornberg, GL, Pope, HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993:13(6):397-408.CrossRefGoogle ScholarPubMed
15.Thase, ME, Jonas, A, Khan, A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008:28(1):13-20.CrossRefGoogle ScholarPubMed
16.Sachs, GS, Collins, MA, Altshuler, LL, et al. Divalproex versus placebo for the treatment of bipolar depression. Poster presented at: 40th Annual Meeting of the American College of Neuropsychopharmacology: December 10, 2001: Waikoloa, Hawaii.Google Scholar
17.Davis, LL, Bartolucci, A, Petty, F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005:85(3):259-266.CrossRefGoogle ScholarPubMed
18.Nierenberg, AA, Ostacher, MJ, Calabrese, JR. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006:163(2):210-216.CrossRefGoogle ScholarPubMed
19.Ketter, TA, ed. Clinical Manual of Bipolar Disorder. Washington, DC: American Psychiatric Publishing. In press.Google Scholar
20.Suppes, T, Webb, A, Paul, B, Carmody, T, Kraemer, H, Rush, AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry. 1999:156(8):1164-1169.CrossRefGoogle Scholar
21.Baldessarini, RJ, Tondo, L, Hennen, J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1999:60(suppl 2):77-84.Google ScholarPubMed
22.Baldessarini, RJ, Tondo, L, Davis, P, Pompili, M, Goodwin, FK, Hennen, J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006:8(5 Pt 2):625-639.CrossRefGoogle ScholarPubMed